onureg
bristol-myers squibb pharma eeig - azacitidín - leukémia, myeloidná, akútna - antineoplastické činidlá - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).
magnerot
wörwag pharma gmbh & co. kg, nemecko - magnéziumorotát - 39 - soli a ionty pro p.o. a parent. aplikÁciu
lisemid 20 mg/10 mg
aflofarm farmacja polska sp. z o.o., poľsko - lizinopril a diuretiká - 58 - hypotensiva
lisemid 20 mg/5 mg
aflofarm farmacja polska sp. z o.o., poľsko - lizinopril a diuretiká - 58 - hypotensiva
lisemid 10 mg/10 mg
aflofarm farmacja polska sp. z o.o., poľsko - lizinopril a diuretiká - 58 - hypotensiva
lisemid 10 mg/5 mg
aflofarm farmacja polska sp. z o.o., poľsko - lizinopril a diuretiká - 58 - hypotensiva
blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - viacnásobný myelóm - antineoplastické činidlá - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
licobondrat 150 mg
adamed czech republic s.r.o., Česká republika - kyselina ibandrónová - 87 - varia i
ibandronic acid stada
stada arzneimittel ag, nemecko - kyselina ibandrónová - 87 - varia i
ibandronic acid mylan 150 mg
mylan ireland limited, Írsko - kyselina ibandrónová - 87 - varia i